DAVID E. I. PYOTT - 18 Feb 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 16:35:48 UTC
Previous filing
09 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PYOTT DAVID E I Director C/O TARSUS PHARMACEUTICALS, 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Scott Sieckert, Attorney-in-Fact 20 Feb 2026 0001051578

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +5,893 $0.000000 5,893 18 Feb 2026 Common Stock 5,893 $63.27 Direct F1
transaction TARS Restricted Stock Units Award $0 +3,729 $0.000000 3,729 18 Feb 2026 Common Stock 3,729 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.